| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0140-6736(91)92594-R |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:014067369192594R?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:014067369192594R?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 1719321 |
| P2093 | author name string | M. E. Billingham | |
| B. M. Meiser | |||
| R. E. Morris | |||
| P2860 | cites work | Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury | Q33564406 |
| Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. | Q43436500 | ||
| Rapamycin for immunosuppression in organ allografting. | Q64891783 | ||
| Cardiac transplant atherosclerosis | Q68177290 | ||
| Lipid mediators in organ transplantation: does cyclosporine accelerate coronary atherosclerosis? | Q68177306 | ||
| The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes | Q69079614 | ||
| Vascular changes in experimental cardiac allografts | Q69250844 | ||
| P433 | issue | 8778 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| P304 | page(s) | 1297-1298 | |
| P577 | publication date | 1991-11-01 | |
| 1991-11-23 | |||
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease | |
| P478 | volume | 338 |
| Q46452741 | Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid |
| Q35253580 | Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction |
| Q53001009 | Allograft conduit wall calcification in a model of chronic arterial graft rejection. |
| Q38822715 | An overview of rapamycin: from discovery to future perspectives |
| Q40906577 | An update on new immunosuppressive drugs undergoing preclinical and clinical trials: potential applications in organ transplantation |
| Q44636622 | Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression. |
| Q43175116 | Benefits of proliferation signal inhibitors beyond immunosuppression. Vascular protection and experience in heart transplantation |
| Q37768655 | Biosynthesis of rapamycin and its regulation: past achievements and recent progress |
| Q33541436 | Chronic rejection and its risk factors |
| Q74617229 | Chronic rejection in cyclosporin A treated renal allograft recipients with allopeptide reactive T cells |
| Q74616554 | Cyclosporine A stimulates proliferation of vascular smooth muscle cells and enhances monocyte adhesion to vascular smooth muscle cells |
| Q77856659 | Cyclosporine does not enhance the development of accelerated coronary artery disease: experimental study in a rat cardiac transplant model |
| Q74214832 | Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy |
| Q45193067 | Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling. |
| Q38525562 | Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study |
| Q44101261 | Effect of rapamycin in combination with calcineurin inhibitors, FK506 and cyclosporin, following arterial injury |
| Q44187062 | Effects of the combination of rapamycin with tacrolimus or cyclosporin on experimental intimal hyperplasia |
| Q40618208 | Graft vessel disease: the impact of immunosuppression and possible treatment strategies |
| Q33535928 | Heart allograft vascular disease: an obliterative vascular disease in transplanted hearts |
| Q92454801 | Hurdles to Cardioprotection in the Critically Ill |
| Q34126617 | Immunosuppressive agents in transplantation: mechanisms of action and current anti-rejection strategies |
| Q74686279 | Immunosuppressive agents: recent developments in molecular action and clinical application |
| Q74571379 | Impact of immunosuppression on coronary endothelial function after cardiac transplantation |
| Q51037879 | In vitro study of drug-eluting stent coatings based on poly(L-lactide) incorporating cyclosporine A - drug release, polymer degradation and mechanical integrity. |
| Q41214653 | In vivo pharmacological effects of ciclosporin and some analogues |
| Q41809927 | Intramural delivery of Sirolimus prevents vascular remodeling following balloon injury. |
| Q61510088 | Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model |
| Q37763755 | Percutaneous coronary interventions in cardiac allograft vasculopathy: a single-center experience. |
| Q35938663 | Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives |
| Q37035703 | Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy |
| Q44444364 | Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E-Deficient Mice |
| Q35072216 | Rapamycin in cardiovascular medicine |
| Q41502331 | Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies |
| Q71986528 | Short-course cyclosporin a therapy for definite allograft valve survival immunosuppression in allograft valve operations |
| Q44420391 | Sirolimus (Rapamycin) Monotherapy Prevents Graft Vascular Disease in Nonhuman Primate Recipients of Orthotopic Aortic Allografts |
| Q44935460 | Sirolimus impairs gonadal function in heart transplant recipients |
| Q34515537 | Sirolimus: a comprehensive review |
| Q34028674 | Sirolimus: continuing the evolution of transplant immunosuppression |
| Q38266183 | Tako-tsubo cardiomyopathy on the first day after renal transplantation - case report and literature review. |
| Q41671287 | Targeting the alloimmune response for prevention of chronic graft loss: efficacy of new immunosuppressive drugs |
| Q52034778 | The peptidyl-prolyl isomerase Pin1 regulates the stability of granulocyte-macrophage colony-stimulating factor mRNA in activated eosinophils. |
| Q33732940 | The potential role of rapamycin in pediatric transplantation as observed from adult studies |
| Q43832381 | Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation |
| Q33146013 | Transplant Coronary Vasculopathy |
| Q47912766 | Transplant vasculopathy |
| Q24792926 | What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? |
| Q74084720 | [Heart transplantation--state of the art today] |
| Q83944047 | [Immunosuppression after heart and lung transplantation] |
Search more.